RSV treatment in infants centers almost entirely on supportive care, not antiviral drugs. There is no widely approved antiviral medication that doctors routinely give babies with respiratory syncytial virus, so the clinical approach focuses on keeping the infant hydrated, clearing mucus from the airways, and providing supplemental oxygen when needed. Most children recover without lasting complications, but the illness can become serious quickly in young or medically fragile babies, making it important for caregivers to understand what hospital treatment involves, what has been shown not to help, and what newer options are emerging.
What Supportive Care Actually Involves
When an infant is hospitalized for RSV, the treatment plan is straightforward in concept but labor-intensive in practice. Nurses and physicians focus on a handful of basics: suctioning mucus from the nose and airways, maintaining fluid balance (often through an IV if the baby is too congested or tired to feed), controlling body temperature, and delivering extra oxygen if blood oxygen levels drop.1MCN: The American Journal of Maternal/Child Nursing. Late Preterm Infants and Risk for RSV The illness resolves without complications in most children, and supportive care remains the standard because decades of research have failed to produce a drug that reliably shortens or eases the course of the infection for the average infant.2PubMed Central. Respiratory syncytial virus: diagnosis, treatment and prevention
Suctioning is one of the most visible parts of RSV care, and parents often assume that deeper, more aggressive suctioning is better. Research suggests otherwise. A prospective study comparing deep suctioning with gentler methods found no difference in respiratory scores or outpatient outcomes, raising the possibility that deep suctioning is not necessary for every infant with bronchiolitis.3PubMed. Suctioning in the management of bronchiolitis: A prospective observational study Gentle bulb suctioning before feeds and sleep is generally sufficient to keep the airways clear enough for the baby to breathe and eat.
Feeding often becomes the most stressful part for caregivers. Infants with significant nasal congestion may refuse the breast or bottle because they cannot coordinate sucking, swallowing, and breathing. Hospital staff typically offer smaller, more frequent feedings, sometimes switching to a slower-flow nipple or using nasogastric tube feeds if oral intake drops dangerously low. Dehydration, not the virus itself, is frequently the tipping point that triggers a hospital admission.
Respiratory Support and High-Flow Oxygen
When an infant’s oxygen saturation dips below safe levels, supplemental oxygen is the first-line respiratory intervention. Over the past decade, high-flow nasal cannula (HFNC) therapy has become increasingly popular in pediatric wards because it delivers warmed, humidified air at higher flow rates than a standard nasal cannula. A large randomized trial published in the New England Journal of Medicine found that infants started on HFNC were about half as likely to need escalation of care compared to those on standard oxygen therapy: roughly 12% versus 23%.4PubMed. A Randomized Trial of High-Flow Oxygen Therapy in Infants with Bronchiolitis That sounds impressive, but the same trial found no significant difference in how long babies stayed in the hospital or how many days they needed oxygen.
Other studies have echoed this nuance. A separate randomized trial of moderate bronchiolitis found that high-flow therapy did not shorten time on oxygen compared to standard treatment, leading the authors to suggest it may not change the underlying disease process. Its real value appeared to be as a rescue therapy: children who failed standard oxygen could often be stabilized with high-flow, potentially avoiding transfer to intensive care.5The Lancet. High-flow warm humidified oxygen versus standard low-flow nasal cannula in moderate bronchiolitis (FAST): an open, randomised controlled trial A quasi-experimental analysis found that patients started on HFNC actually spent longer on oxygen and in the hospital than those on standard therapy, though the HFNC patients tended to be sicker to begin with, which complicates the comparison.6Pediatric Pulmonology. High‐flow nasal cannulas versus standard oxygen therapy for moderate bronchiolitis: A quasi‐experimental analysis The takeaway for parents: HFNC is a useful tool, especially for preventing ICU transfers, but it is not a cure. It buys time while the baby’s immune system does the real work.
Treatments That Do Not Work
One of the most frustrating aspects of RSV for parents is the long list of medications that seem like they should help but consistently fail to make a difference. Bronchodilators like albuterol, the go-to for childhood asthma, are commonly requested or even prescribed during RSV episodes. Yet a Cochrane systematic review found that bronchodilators do not improve oxygen levels, do not reduce hospital admissions, do not shorten hospital stays, and do not speed up recovery at home.7PubMed Central. Bronchodilators for bronchiolitis The problem is that RSV bronchiolitis involves inflammation and mucus plugging in tiny airways, not the kind of airway muscle spasm that bronchodilators are designed to relieve.
Corticosteroids, another staple of asthma management, fare no better. A systematic review of pharmacologic treatments for bronchiolitis found no convincing evidence that steroids improve overall outcomes compared with supportive care alone. The same review examined nebulized epinephrine and reached a similar verdict: aside from some temporary improvements in clinical scores, epinephrine did not produce meaningful benefit.8Archives of Pediatrics & Adolescent Medicine. Pharmacologic Treatment of Bronchiolitis in Infants and Children: A Systematic Review These findings explain why current clinical guidelines strongly discourage routine use of any of these medications for RSV bronchiolitis. It is worth knowing this because emergency departments still sometimes administer a “trial” of albuterol, and parents should not be alarmed if it does not seem to help.
The Hypertonic Saline Question
Nebulized hypertonic saline (a saltier-than-normal saline solution) is one treatment that has generated genuine debate rather than a clean negative result. A Cochrane review pooling data from 21 trials found that hospitalized infants given hypertonic saline may have had a slightly shorter hospital stay, on the order of about half a day less than infants given normal saline or standard care.9PubMed Central. Nebulised hypertonic saline solution for acute bronchiolitis in infants That sounds modest, and the Cochrane reviewers flagged the evidence as low certainty. Meanwhile, a multicenter randomized trial specifically in infants with moderately severe RSV bronchiolitis found no significant difference in length of stay between hypertonic and normal saline groups.10PubMed. Nebulized hypertonic saline in infants hospitalized with moderately severe bronchiolitis due to RSV infection: A multicenter randomized controlled trial The treatment was well tolerated with no adverse effects, so some hospitals still use it, but the evidence for benefit is thin. If your infant’s care team offers hypertonic saline, it is unlikely to hurt; whether it helps is genuinely unclear.
Prevention With Monoclonal Antibodies
Because direct treatment options are so limited, the biggest advances in RSV care for infants have come on the prevention side. The older option, palivizumab, is a monoclonal antibody given as monthly injections throughout RSV season. It works by blocking the virus from entering cells, but its cost and the need for repeated doses limited its use to narrowly defined high-risk groups, mainly very premature infants and those with chronic lung or heart disease.11PubMed Central. Systematic Review: Efficacy, Safety Profile, and Cost-Effectiveness of Nirsevimab Versus Palivizumab for RSV Prevention in Children Under 24 Months
Nirsevimab, approved more recently, is a longer-acting antibody that requires just a single injection before or during RSV season. In a large trial, nirsevimab reduced RSV-related hospitalizations by about 83% compared with standard care, with roughly three-tenths of a percent of immunized infants hospitalized versus one and a half percent of those who were not.12PubMed. Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants Real-world data have backed this up. A case-control study at a tertiary pediatric hospital found an estimated effectiveness of about 91%, with immunized infants spending fewer days in the hospital and being far less likely to need intensive care than unimmunized infants.13PubMed Central. Assessing the Impact of Nirsevimab Immunization on RSV Bronchiolitis Hospital Admissions and Their Severity: A Case-Control Study and Comparison With Pre- and Post-COVID-19 Seasons in a Tertiary Pediatric Hospital Because nirsevimab is a single dose and appears cost-effective for broader populations, many countries have moved toward recommending it for all infants entering their first RSV season rather than restricting protection to high-risk babies.14PubMed Central. Disease Burden Associated with All Infants in Their First RSV Season in the UK: A Static Model of Universal Immunization with Nirsevimab Against RSV-Related Outcomes
Maternal Vaccination
A complementary strategy is vaccinating pregnant women so that their antibodies cross the placenta and protect the newborn during those vulnerable first months. RSV-specific antibodies transfer efficiently from mother to baby: in a study in rural Nepal, maternal and infant cord blood antibody levels were highly correlated, with a transfer ratio close to 1-to-1.15PubMed Central. Transplacental transfer of maternal respiratory syncytial virus (RSV) antibody and protection against RSV disease in infants in rural Nepal Newer research has shown that maternal RSV vaccination generates high-quality, affinity-matured antibodies that are selectively transported across the placenta, providing passive immunity to infants after birth.16Nature Communications. Maternal RSV vaccination generates high-affinity antibodies that efficiently transfer to infants, providing enhanced passive immunity
There is an important caveat: early preterm infants showed reduced antibody transfer efficiency compared with full-term babies.17Nature Communications. Maternal RSV vaccination generates high-affinity antibodies that efficiently transfer to infants, providing enhanced passive immunity This means the babies at highest risk from RSV may get the least benefit from maternal vaccination alone, which is one reason why direct infant immunization with nirsevimab remains important for preterm infants.
Which Infants Face the Greatest Risk
Nearly all children encounter RSV by age two, and most handle it like a bad cold. The infants who end up seriously ill tend to share certain characteristics. Prematurity, chronic lung disease, congenital heart disease, neuromuscular conditions, immune deficiency, and Down syndrome all substantially increase the risk of severe RSV lower respiratory tract infection.18PubMed Central. Risk factors for severe respiratory syncytial virus lower respiratory tract infection Beyond underlying medical conditions, several environmental and demographic factors matter: being younger than six months at the start of RSV season, having young siblings at home, exposure to cigarette smoke, crowded living conditions, and male sex have all been linked to worse outcomes.19PubMed Central. Risk factors for severe respiratory syncytial virus lower respiratory tract infection
A large nationwide cohort study reinforced several of these risk factors and quantified their impact on the most severe outcomes. Being born small for gestational age, being part of a multiple birth, having siblings under four years old, and being born during winter were among the factors most strongly associated with ICU admission or death.20The Lancet Regional Health – Europe. Risk factors for severe respiratory syncytial virus disease in children: a nationwide register-based cohort study For parents, the practical message is that a winter-born baby with an older toddler sibling in the house is in a meaningfully higher-risk category, even if the baby is otherwise healthy.
When Bacteria Complicate the Picture
RSV opens the door to secondary bacterial infections more often than many caregivers realize. A large systematic review and meta-analysis found that about 29% of RSV-infected children had at least one bacterial pathogen detected alongside the virus.21PubMed. Bacteria in RSV-infected children: A systematic review and meta-analysis in the context of recent microbiome research The three most commonly identified bacteria were Moraxella catarrhalis, Streptococcus pneumoniae, and Haemophilus influenzae. Children with bacterial co-detection were more likely to develop fever, had higher inflammatory markers, and experienced worse outcomes including longer hospital stays and greater need for respiratory support.22PubMed. Bacteria in RSV-infected children: A systematic review and meta-analysis in the context of recent microbiome research
This is where antibiotics enter the conversation. Antibiotics do nothing against RSV itself, but when a secondary bacterial infection takes hold, particularly pneumonia or acute otitis media (ear infection), antibiotics become appropriate and sometimes critical. Earlier research documented that bacterial infection was observed in about 39% of children hospitalized with RSV, underscoring the virus’s role as a predisposing agent for secondary bacterial infections in the airways.23PubMed. Bacterial coinfection in children hospitalized with respiratory syncytial virus infections If your infant develops a new fever after seeming to improve, or if symptoms worsen after several days, a bacterial complication is one reason the pediatrician may re-evaluate.
Viral Co-Infections and Disease Severity
Parents sometimes worry that catching RSV along with another virus, such as rhinovirus, will make the illness dramatically worse. The evidence on this is surprisingly counterintuitive. A study of hospitalized children found that about half had RSV alone, while nearly half had RSV alongside another virus, most commonly rhinovirus. After adjustment, neither rhinovirus co-infection nor co-infection with other viruses was associated with increased disease severity compared to RSV alone.24PubMed Central. Disease Severity of Respiratory Syncytial Virus Infection in Hospitalized Children In fact, one study found that infants with RSV alone actually had higher ICU admission rates and longer hospital stays than those with co-infections, though the authors cautioned that the small sample size limited firm conclusions.25PubMed Central. Risk Factors Associated with Severe RSV Infection in Infants: What Is the Role of Viral Co-Infections?
There is some evidence that RSV and rhinovirus actually interfere with each other at the population level, so that the presence of one may reduce the likelihood of acquiring the other. However, when co-infection does occur, symptom duration tends to be a few days longer.26PubMed. Interference between respiratory syncytial virus and rhinovirus in respiratory tract infections in children The bottom line is that viral co-infection does not appear to be the danger multiplier parents might assume.
New Antivirals on the Horizon
The biggest gap in RSV care has always been the absence of a safe, effective antiviral that can be given directly to sick infants. Ribavirin, the only antiviral with any historical use in RSV, carries a significant side-effect profile and high cost. Current guidance limits it to patients at risk for the most serious complications.27PubMed Central. Pediatric Antiviral Stewardship: Defining the Potential Role of Ribavirin in Respiratory Syncytial Virus-Associated Lower Respiratory Illness In practice, most hospitals rarely use it.
That landscape is beginning to change. Ziresovir, a small-molecule antiviral that targets the RSV polymerase, has produced encouraging results in randomized trials of hospitalized infants six months and younger. In a phase 3 trial, infants receiving ziresovir showed a significantly greater improvement in bronchiolitis clinical scores by day three compared with placebo, along with a greater reduction in viral load by day five.28PubMed. Ziresovir in Hospitalized Infants with Respiratory Syncytial Virus Infection A follow-up phase 3 trial with 24-month follow-up confirmed these findings: the clinical score improvement was again significantly better with ziresovir, with no drug-related serious adverse events and no deaths.29PubMed. Efficacy and safety of ziresovir in hospitalised infants aged 6 months or younger with respiratory syncytial virus infection in China: findings from a phase 3 randomised trial with 24-month follow-up Ziresovir is not yet widely available, but it represents a genuine step toward having a treatment that fights the virus directly rather than just managing symptoms.
Beyond ziresovir, the pipeline of RSV antiviral candidates has expanded considerably. For decades, drug development was dominated by compounds targeting how the virus enters cells. More recent candidates aim at different parts of the viral machinery, including the polymerase complex and the nucleoprotein, which broadens the range of potential therapeutic targets.30PubMed Central. Status of advanced respiratory syncytial virus antiviral therapeutics 2025 Whether any of these drugs eventually become standard of care depends on how they perform in larger, more diverse populations and whether they meaningfully reduce the need for hospitalization or intensive care, not just improve a clinical score.
How RSV Is Diagnosed
Diagnosis matters because confirming RSV can guide decisions about isolation, whether to pursue antibiotics for a possible bacterial cause, and which patients might qualify for specific treatments. Two main categories of tests exist: rapid antigen detection tests and molecular tests based on PCR. Rapid antigen tests can return results in under 30 minutes, but their sensitivity is imperfect. A systematic review and meta-analysis of 71 studies found that the overall sensitivity of rapid antigen tests was about 80% in children, meaning roughly one in five positive cases could be missed.31PubMed Central. Diagnostic Accuracy of Rapid Antigen Detection Tests for Respiratory Syncytial Virus Infection: Systematic Review and Meta-analysis Specificity was consistently high at about 97%, so a positive result is reliable.
A more recent meta-analysis focusing specifically on pediatric data found that the pooled sensitivity of rapid antigen tests was around 75% when measured against the gold standard of RT-PCR, and was even lower, about 63%, in studies limited to children aged five and under.32PubMed Central. Pediatric Respiratory Syncytial Virus Diagnostic Testing Performance: A Systematic Review and Meta-analysis Molecular tests with rapid turnaround times offer better accuracy, with sensitivity ranges from about 67% to 100% and specificity above 94%.33The Journal of Applied Laboratory Medicine. Diagnostic Accuracy of Commercially Available Tests for Respiratory Syncytial Virus: A Scoping Literature Review in the COVID-19 Era In practice, many emergency departments use a rapid antigen test first and confirm negative results with PCR if RSV is strongly suspected clinically.
What Caregivers Can Watch for at Home
Most RSV infections are managed at home. The decision to seek medical care often comes down to how well the baby is breathing and feeding. Research into caregiver experiences found that parents who sought medical attention most often described noticing that their child’s breathing or heartbeats seemed faster than usual.34PubMed Central. Validation of a caregiver diary to monitor severity and recovery of pediatric patients with respiratory syncytial virus infection You do not need to formally count breaths per minute. If the baby’s breathing looks labored, the nostrils are flaring, the skin between the ribs is pulling in with each breath, or the baby is too tired or congested to eat, those are signs to call the pediatrician or head to an emergency department.
Dehydration red flags include fewer than three wet diapers in 24 hours, a dry mouth, or no tears when crying. Color changes around the lips or fingertips (a bluish or grayish tinge) signal dangerously low oxygen and warrant an immediate emergency visit. RSV symptoms typically peak around days three to five and then gradually improve, so worsening after that window is also a reason to seek evaluation for a possible secondary bacterial infection.
Long-Term Respiratory Effects
One of the more concerning aspects of RSV is what happens after the acute illness resolves. A growing body of evidence links severe RSV lower respiratory tract infections in the first few years of life with recurrent wheezing and asthma-like symptoms later in childhood. Studies with follow-up periods of up to 25 years have reported recurrent wheezing rates ranging from 4% to 47% and asthma rates from 8% to 76%, depending on the population studied and the definitions used.35PubMed Central. The Burden and Long-term Respiratory Morbidity Associated with Respiratory Syncytial Virus Infection in Early Childhood Those ranges are wide, which reflects the difficulty of separating RSV’s direct effects from genetic predisposition and other environmental exposures.
Whether RSV actually causes asthma or simply reveals children who were already predisposed remains an active debate. Early-life RSV infections are increasingly recognized as a significant risk factor, even if the causal chain is not fully settled.36PubMed. The impact of respiratory syncytial virus on asthma development and exacerbation Part of the explanation may lie in the immune response itself. Severe RSV disease appears to be driven not only by the virus replicating in the lungs but by a dysregulated immune reaction, including excessive inflammation and airway remodeling, that can persist after the infection clears.37PubMed Central. Immunomodulation in Respiratory Syncytial Virus Infection: Mechanisms, Therapeutic Targets, and Clinical Implications This is one more reason that preventing severe RSV infection in the first place, through monoclonal antibodies or maternal vaccination, may have benefits that extend well beyond the first winter of life.